HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system-Reference-Cited by-同舟云学术

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system

Published:2014-07-26 Issue:1 Volume:14 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Bonde Jesper,Rebolj Matejka,Ejegod Ditte Møller,Preisler Sarah,Lynge Elsebeth,Rygaard Carsten

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/1471-2334-14-413.pdf

Reference31 articles.

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.

2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009, 10: 321-322. 10.1016/S1470-2045(09)70096-8.

3. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ: Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012, 13: 78-88. 10.1016/S1470-2045(11)70296-0.

4. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010, 11: 249-257. 10.1016/S1470-2045(09)70360-2.

5. Franco EL, Cuzick J, Hildesheim A, de Sanjose S: Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006, 24 (Suppl 3): 171-177.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cervical cancer screening integrated in routine clinical care of women with HIV;AIDS;2024-06-27

2. Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening;British Journal of Cancer;2024-04-13

3. Prevalence of cervical human papillomavirus and the risk of anal co‐infection in kidney transplant recipients: Results from a Danish clinical study;Transplant Infectious Disease;2023-02-07

4. Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus–positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden;PLOS ONE;2022-09-22

5. Incidence of oncogenic HPV and HPV-related dysplasia five years after a negative HPV test by self-sampling in elderly women;Infectious Agents and Cancer;2022-08-03